brigatinib

September 2, 2016September 2, 2016

Potential Treatment for Advanced Non-Small Cell Lung Cancers Before FDA for Approval

Lung Cancer, News

ARIAD Pharmaceuticals announced that it has completed the New Drug Application for brigatinib it filed with the U.S. Food and Drug Administration (FDA), seeking market approval to use the treatment in patients with metastatic ... Read more

July 15, 2016July 15, 2016

Center Enrolls First Lung Cancer Patient in Advanced Phase 3 Clinical Trial

Lung Cancer, News

For 40 years, Virginia Cancer Specialists (VCS) has contributed to the campaign against cancer and diseases of the blood by offering advanced technology, treatment and early detection. For residents of ... Read more

April 21, 2016April 21, 2016

Specific Non-small Cell Lung Cancer Patients Show Improvement in ARIAD’s Clinical Trial for Brigatinib

News

ARIAD Pharmaceuticals recently presented updated data from an ongoing Phase 1/2 trial testing brigatinib, an investigational tyrosine kinase inhibitor, in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) ... Read more

April 14, 2016April 14, 2016

Phase 3 Trial of Brigatinib for Non-Small Cell Lung Cancer Linked to ALK Mutations Is Launched by ARIAD

Lung Cancer, News

ARIAD Pharmaceuticals recently announced the start of a Phase 3 clinical trial of brigatinib for locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with mutations in the anaplastic ... Read more